Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 27, 2007 Brian Lawler	ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note.
The Motley Fool April 17, 2008 Brian Lawler	The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.
The Motley Fool August 6, 2007 Brian Lawler	Don't Discount ViroPharma The exciting biopharma announces its second-quarter financial results. Considering that its lead drug is highly profitable and has two strong pipeline candidates in development, shares of ViroPharma don't look expensive.
The Motley Fool October 31, 2007 Brian Lawler	The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note.
The Motley Fool June 13, 2007 Brian Lawler	ViroPharma Is on Its Way ViroPharma completes preliminary enrollment in a study of one of its drug candidates. Investors, take note.
The Motley Fool December 16, 2011 Brian Orelli	Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool August 11, 2010 Brian Orelli	Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
The Motley Fool February 28, 2008 Brian Lawler	ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline.
The Motley Fool April 29, 2008 Brian Lawler	So Pharmasset, So Good Early data hints at a promising hepatitis C treatment.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
The Motley Fool November 21, 2007 Brian Lawler	Black Friday Bargain Stock: ViroPharma Is ViroPharma a good value right now? With competition worries out of the way, and a strong and growing cash flow, it won't take much success for value investors to be rewarded.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool November 8, 2007 Brian Lawler	Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note.
The Motley Fool January 8, 2008 Brian Lawler	InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C.
The Motley Fool May 7, 2007 Brian Lawler	ViroPharma Victorious A strong first quarter helps the pharmaceutical storm into 2007. Investors, take note.
The Motley Fool June 15, 2007 Brian Lawler	Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week.
The Motley Fool July 16, 2007 Brian Lawler	Idenix Gets Stopped It's been a bad two months for Idenix Pharmaceuticals. First, negative data for its hepatitis drug candidate, valopicitabine; now the FDA has put a stop to all testing of the drug.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool October 31, 2011 Brian Orelli	Gunning for the Leaders Hepatitis C drugs take center stage.
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
Nurse Practitioner July 2010 Christine S. Brennan	Overcoming barriers to new treatment options for hepatitis C This article reviews current guidelines for HCV treatment and proposes strategies to overcome potential barriers to state-of-the-art therapy.
The Motley Fool April 19, 2005 Charly Travers	A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year.
The Motley Fool July 27, 2011 Brian Orelli	Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.
The Motley Fool April 25, 2008 Brian Lawler	Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug.
The Motley Fool January 19, 2012 Brian Orelli	New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go.
The Motley Fool April 30, 2008 Brian Lawler	ViroPharma: Risky and Exciting Solid lead drug, meet promising pipeline candidate.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool November 3, 2006 Brian Lawler	Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future.
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
The Motley Fool May 10, 2011 Brian Orelli	Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet.
The Motley Fool July 27, 2011 Alexander Crawford	Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve?
The Motley Fool September 28, 2007 Brian Orelli	Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note.
The Motley Fool November 29, 2010 Brian Orelli	Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
Chemistry World December 9, 2009 Sarah Houlton	New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
The Motley Fool April 30, 2008 Brian Lawler	Idenix Aims for a Comeback This drugmaker may be down, but it's not yet out.
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
Nurse Practitioner December 2009 Gujral & Collantes	Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
The Motley Fool January 9, 2012 Travis Hoium	Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug.
The Motley Fool May 17, 2011 Luke Timmerman	Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex.
The Motley Fool October 5, 2010 Brian Orelli	You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent.
The Motley Fool January 9, 2007 Brian Lawler	ViroPharma's Healthy Sales Guidance The coming year looks like another strong one for the drug developer. This small-cap pharmaceutical stock is worth taking a look at just for its cheap valuation.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.